Coalition of Amici File Brief in Support of Myriad

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

[author: Kevin E. Noonan]

BIOThe Biotechnology Industry Organization (BIO), joined by the Association of University Technology Managers (AUTM) and the Coalition for 21st Century Medicine filed an amicus brief in support of Myriad (unlike many other amici on both sides of the issue, who wrote ostensibly "in support of neither party").  Authored by a group including Seth Waxman, former U.S. Solicitor General, and Hans Sauer of BIO, the brief argues that the patent-eligibility of isolated DNA claims is unchanged by the Supreme Court's decision in Mayo v. Prometheus.  First, the brief argues that the Mayo decision simply does not apply to composition of matter claims.  Second, that the procedural posture of the case, where the Court granted certiorari, vacated the former panel opinion, and remanded does not in any way imply that the Supreme Court thinks that its Mayo decision applies to composition of matter claims.  Finally, the brief argues that it would be error having "far-reaching negative consequences" for the Federal Circuit to apply Mayo to defeat the patent-eligibility of Myriad's composition of matter claims.  The brief also contains a short section regarding the continued patent eligibility of claim 20 of U.S. Patent No. 5,747,282 (the screening method claim that was the subject of an alternative view in an amicus brief filed by Eli Lilly & Co.; see "Eli Lilly & Co. File Amicus Brief in AMP v. Myriad").

AUTMThe first argument set forth in the brief is that the Court's Mayo decision is limited to "policing" the line between laws of nature and their applications in methods of applying such laws.  This decision did not "alter the proper framework for analyzing manufacture or composition of matter claims," according to the brief, and that precedent is governed by Diamond v. Chakrabarty.  The brief then assesses the Court's Mayo decision (which was on its own terms limited to "an examination of the particular claims before [it]").  The Court's decision was ultimately based on its conclusion that the claims at issue in Mayo "simply tell a doctor about the relevant natural laws" and do not "require any change in treatment or other action" on a doctor's part.  The claims in Mayo were not patent-eligible, according to the brief, because "this bare recitation of an idea combined with what the Court deemed to be insignificant steps placed the claim squarely within the contours of prior decisions prohibiting the preemption of abstract ideas or principles."  This "framework" for performing the Court's analysis in Mayo was not new, according to amici, being "already in place when [the Federal Circuit] issued its [now-vacated] panel decision" and this precedent "did not affect [the Federal Circuit's] analysis of the Myriad composition claims" ("and rightly so" says the brief).  This is because "it makes no sense" to apply the Court's analytic methods for assessing the patent-eligibility of a method claim to a manufacture or composition of matter claim.  The very language of the Court's Mayo decision, requiring an assessment of whether a claim "merely 'append[s] conventional steps' to a law of nature" does not apply because "[c]omposition of matter claims do not have 'steps.'"  This is not mere semantics, because as the brief points out compositions of matter have "physical form and can be claimed without regard to the manner in which they are made or used."  (This latter point is an important one, because it illustrates why a broad, undifferentiated "product of nature" ban would also preclude patenting of a synthetic form of a natural product that did not differ in physical structure from the product as it is found in nature.)  The brief cites Chakrabarty as well as Funk Bros. Seed Co. v. Kalo Inoculant Co. for the proposition that the Supreme Court has already set forth the proper measure for the patent-eligibility of a manufacture or composition of matter, i.e. "whether the claimed invention has different characteristics and uses from the naturally occurring analogue."  This standard, of course, was applied by the panel majority in deciding that Myriad's isolated DNA claims were patent-eligible when the case was last before the Federal Circuit, as amici remind the remand panel.

The brief further argues that it could not have been the Supreme Court's intention to require the rubrics enunciated in Mayo to apply to manufacture and composition of matter claims, because if it did the Court would have included Chakrabarty and Funk Bros. in its "consideration of the controlling precedents."  On the contrary, the brief reminds the Federal Circuit that those precedents were completely omitted from the Supreme Court's opinion, which "strongly implies that the Court did not consider" these cases, and thus Mayo does not control the Court's assessment of patent-eligibility for Myriad's DNA claims.  Calling the Court's delineation of patent-eligibility of manufacture and composition of matter claims in Chakrabarty a "careful textual analysis" of Section 101, the brief argues that the Court did not discard it "in favor of a free-floating 'products of nature' exception," reminding the Federal Circuit that "the Supreme Court specifically 'cautioned that courts 'should not read into the patent laws limitations and conditions which the legislature has not expressed.''"  Applied to "products of  nature," the brief asserts that its patent-eligibility might be compromised only if there was "a complete absence of human involvement," a standard consistent with the earlier panel decision and not changed, amici argue, by the Court's Mayo decision.

Turning to the procedural posture of the case, the brief notes that "grant [certiorari], vacate and remand" decisions are "a regular consequence of an intervening Supreme Court decision" and does not imply that a Court of Appeals' earlier decision was incorrect, citing Hughes Aircraft Co. v. U.S., 140 F.3d 1470, 1473 (Fed. Cir.1998)The brief then revisits a pair of cases directly on point, Chakrabarty and it companion case, In re Bergy.  In those cases (which were heard by the Federal Circuit's predecessor court, the Court of Customs and Patent Appeals), on remand the Court, and specifically Judge G.S. Rich, decided that the intervening Supreme Court decision there, Parker v Flook, was "'inapplicable' because 'Flook was concerned only with the question of what is a "process" under 101,'" in contrast to the issue in Chakrabarty and Bergy, which "involve[d] only the construction of the terms 'manufacture, or composition of matter.'"  Ultimately, in Chakrabarty, the Supreme Court agreed (and, the brief notes that the Court in Chakrabarty did not "dissect the claimed microorganism into its individual components" but rather considered the claims "as a whole").  The CCPA avoided error in determining that Flook was not relevant to its assessment of the manufacture and composition of matter claims before it, and the brief argues that coming to the opposite conclusion here, by changing the Federal Circuit's opinion in the face of Mayo, would be error.

Finally, the brief turns on the negative consequences of a patent-eligibility ban on Myriad's DNA claims (as it must, because this is ultimately more a policy question than a legal one).  Here amici argue that the policy balance "overwhelmingly favors [the Federal Circuit's] earlier determination that isolated genomic DNA and cDNA are patentable subject matter," based on "[n]umerous studies [that] have refuted the claim that patents on isolated genomic DNA or cDNA molecules 'inhibit future innovation' or 'impede the flow of information.'"  In addition to several cited studies supporting this argument, the brief also notes that the question of whether the scope of Myriad's DNA claims "are unduly 'preemptive' cannot be substantiated or resolved without examining what activities actually infringe such claims, something that is strikingly absent from plaintiffs' case" (as is any attempt to construe the claims by either the parties or the courts).  The brief notes that "it is highly questionable" whether the isolated DNA claims would be infringed by sequencing the BRCA genes, either using existing technologies or as part of "whole genome sequencing," "because such techniques do not require isolation of the gene being sequenced."  The brief also uses rapamycin and modified analogues thereof to illustrate the unnecessary complications and uncertainties that would arise should Mayo's analytical framework for assessing the patent-eligibility of method claim be unwisely extended to manufacture and composition of matter claims.  And the brief includes several examples of how "[r]eliable patent protection is critical to the discovery, disclosure and commercialization of new and useful compositions of matter that are isolated or derived from natural sources," including erythropoietin, rapamycin, muromonab-CD3 (a mouse monoclonal antibody used to prevent transplant rejection), phytase (an enzyme used as a cattle feed component to reduce environmental phosphate pollution), and isolated enzymes used in the biofuels industry.  The brief also is careful to remind the Court that in all these instance and others, patenting "can speed the pace of innovation by encouraging the inventor to disclose the invention and make it available to other researchers," and that the fact that patents expire must be contrasted with the eternal availability of the patent disclosure.

The final section of the brief, comprising a single paragraph, relates to claim 20 of Myriad's '282 patent:

20.  A method for screening potential cancer therapeutics which comprises:  growing a transformed eukaryotic host cell containing an altered BRCA1 gene causing cancer in the presence of a compound suspected of being a cancer therapeutic, growing said transformed eukaryotic host cell in the absence of said compound, determining the rate of growth of said host cell in the presence of said compound and the rate of growth of said host cell in the absence of said compound and comparing the growth rate of said host cells, wherein a slower rate of growth of said host cell in the presence of said compound is indicative of a cancer therapeutic.

The patent-eligibility analysis for this claim "need not detain [the Court] long," according to the brief, because the claim includes the step of "growing a transformed eukaryotic cell containing an altered BRCA 1 gene."  The transformed cell itself being novel, the brief argues that its use "cannot be the type of 'well-understood, routine, conventional activity already engaged in by the scientific community' required by the Mayo decision to render a claim patent-ineligible."

For additional information regarding this topic, please see:

• "Dr. James Watson: Human Genes Should Not Be Patented," July 12, 2012
• "Scientist-Law Professor Files Amicus Brief in Myriad Case," July 11, 2012
• "U.S. Government: Mayo Decision Supports Prior Argument That Isolated Genomic DNA Is Not Patent Eligible," July 10, 2012
• "IPO Amicus Brief Argues for Patent Eligibility of Myriad's Isolated DNA Claims and Method Claim 20," July 9, 2012
• "Eli Lilly & Co. File Amicus Brief in AMP v. Myriad," June 27, 2012
• "Parties and Amici File Briefs in Myriad Case," June 17, 2012

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.